Disorders of lipoprotein metabolism are collectively referred to as ‘dyslipidemia’. Many patients with dyslipidemia are at increased risk for atherosclerotic cardiovascular disease. Recently, in a short review of published homoeopathy research evidences on dyslipidaemia identified four preclinical, three observational studies, and two case records. There were positive leads in managing patients suffering from dyslipidaemia. However, more well-designed studies were warranted to generate effectiveness/efficacy of homeopathy. In order to detect the efficacy of individualized homeopathic medicines in treatment of dyslipidemia, this double blind, randomized (1:1), placebo-controlled, two parallel arms, clinical trial will be conducted on 92 patients at National Institute of Homoeopathy (NIH). Patients will be randomized to receive either individualized homeopathic medicines in centesimal potencies, or identical looking placebo. Irrespective of groups, all the randomized patients will be advised for dietary restriction (low saturated fat and high fiber) and regular exercises. The outcome measures - LDLc (primary), VLDLc, HDLc, total cholesterol, triglycerides, and MYMOP-2 (secondary) will be assessed at baseline, and every month, up to 6 months. Comparative analysis will be carried out to detect group differences. Results will be published in scientific journals.